Compare BHAT & RFL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BHAT | RFL |
|---|---|---|
| Founded | 2010 | 2017 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Recreational Games/Products/Toys | Real Estate |
| Sector | Consumer Discretionary | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 27.7M | 61.1M |
| IPO Year | 2018 | 2017 |
| Metric | BHAT | RFL |
|---|---|---|
| Price | $1.43 | $1.50 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 70.3M | 89.3K |
| Earning Date | 01-01-0001 | 03-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 28.28 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $917,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 43.96 |
| 52 Week Low | $0.02 | $1.12 |
| 52 Week High | $3.94 | $3.19 |
| Indicator | BHAT | RFL |
|---|---|---|
| Relative Strength Index (RSI) | 70.57 | 72.54 |
| Support Level | $1.12 | $1.41 |
| Resistance Level | $2.05 | $1.64 |
| Average True Range (ATR) | 0.04 | 0.10 |
| MACD | 0.17 | 0.02 |
| Stochastic Oscillator | 76.98 | 75.00 |
Blue Hat Interactive Entertainment Technology is focused on commodity trading, including chemicals, jewelry, and precious metals such as gold. It operates a gold and diamond trading and supply chain business. Its business model encompasses physical gold trading, diamond trading, gold derivatives trading, and the development of AI-enabled trading platforms. Its segments include Diamond trading, Commodity trading, Information service, Interactive toys - animation series, and Interactive toys - game series. It derives revenue from Diamond trading. The majority of its revenues are generated in PRC.
Rafael Holdings Inc is a biotechnology firm that develops pharmaceuticals and invests in clinical and early-stage companies in pharmaceuticals and medical devices. Trappsol Cyclo is in Phase 3 trials for Niemann-Pick Disease Type C1. The company focuses on completing these trials, seeking regulatory approval, and commercializing the product. It also invests in portfolio companies including Cyclo, LipoMedix, Barer, Rafael Medical Devices, Cornerstone, and Day Three, targeting therapeutics for unmet medical needs. The business operates through three segments: Healthcare, Infusion Technology, and Real Estate. Operations are based in the United States and Israel.